Acurx Pharmaceuticals (NASDAQ:ACXP) Shares Up 0.7% – Here’s What Happened

Shares of Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) rose 0.7% during mid-day trading on Wednesday . The company traded as high as $1.3849 and last traded at $1.37. 58,591 shares traded hands during trading, a decline of 33% from the average daily volume of 87,142 shares. The stock had previously closed at $1.36.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Acurx Pharmaceuticals in a research note on Friday, July 17th. One investment analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of “Hold” and an average price target of $31.00.

Acurx Pharmaceuticals Price Performance

The firm has a market cap of $7.62 million, a P/E ratio of -0.51 and a beta of -2.02. The company’s 50 day moving average is $1.44 and its two-hundred day moving average is $2.09.

Acurx Pharmaceuticals (NASDAQ:ACXP) last issued its quarterly earnings results on Thursday, August 13th. The company reported ($0.53) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.38) by ($0.15). Research analysts predict that Acurx Pharmaceuticals, Inc. will post -2 EPS for the current year.

About Acurx Pharmaceuticals

Acurx Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel antibiotics for serious bacterial infections. The company’s approach centers on targeting bacterial DNA polymerase IIIC, an enzyme required for the replication of certain bacteria and distinct from targets used by many existing antibiotics.

Acurx’s lead product candidate is ibezapolstat, an orally administered antibiotic being developed for the treatment of Clostridioides difficile infection, commonly known as C.